Identification of a distinct population of CD133 + CXCR4 + cancer stem cells in ovarian cancer

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Cioffi, Michele ^a   Dalterio, Crescenzo ^a   Camerlingo, Rosalba ^a   Tirino, Virginia ^a   Consales, Claudia ^a   Riccio, Anna ^a   Ieranò, Caterina ^a   Cecere, Sabrina Chiara ^a   Losito, Nunzia Simona ^a   Greggi, Stefano ^a   Pignata, Sandro ^a   Pirozzi, Giuseppe ^a   Scala, Stefania ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD133 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; CISPLATIN; CXCR4 PROTEIN, HUMAN; GLYCOPROTEIN; LEUKOCYTE ANTIGEN; PEPTIDE; PROM1 PROTEIN, HUMAN; PROM1 PROTEIN, MOUSE;

ANIMAL; BIOSYNTHESIS; CANCER STEM CELL; CELL LINEAGE; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; GENETICS; HCT 116 CELL LINE; HUMAN; MOUSE; OVARY TUMOR; PATHOLOGY;

AC133 ANTIGEN; ANIMALS; ANTIGENS, CD; CELL LINEAGE; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; GLYCOPROTEINS; HCT116 CELLS; HUMANS; MICE; NEOPLASTIC STEM CELLS; OVARIAN NEOPLASMS; PEPTIDES; RECEPTORS, CXCR4;

EID: 84930683609     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep10357     Document Type: Article

References (47)

1. Visvader, J.E. & Lindeman, G.J. Cancer stem cells in solid tumors: Accumulating evidence and unresolved questions. Nat. Rev. Cancer 8, 755-768 (2008).
2. Bhatia, M., Bonnet, D., Murdoch, B., Gan, O.I. & Dick, J.E. A newly discovered class of human hematopoietic cells with SCIDrepopulating activity. Nat. Med. 4, 1038-1045 (1998).
3. Scopelliti, A. et al. Therapeutic implications of Cancer Initiating Cells. Expert Opin. Biol. Ther. 9, 1005-1016 (2009).
4. Li, L. & Bhatia, R. Stem cell quiescence. Clin. Cancer Res. 17, 4936-4941 (2011
5. Hermann, P.C., Bhaskar, S., Cioffi, M. & Heeschen, C. Cancer stem cells in solid tumors. Semin. Cancer Biol. 20, 77-84 (2010).
6. Shoemaker, R.H. The NCI 60 human tumour cell line anticancer drug screen. Nat. Rev. Cancer 6, 813-823 (2006).
7. Ross, D.T. et al. Systematic variation in gene expression patterns in human cancer cell lines. Nat. Genet. 24, 227-235 (2000).
8. Weigmann, A., Corbeil, D., Hellwig, A., Huttner & W.B. Prominin, a novel microvilli-specific polytopic membrane protein of the apical surface of epithelial cells, is targeted to plasmalemma l protrusions of non-epithelial cells. Proc. Natl. Acad Sci. USA. 94, 12425-12430 (1997).
9. Yin, A.H. et al. AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood. 90, 5002-5012 (1997).
10. Vercauteren, S.M. & Sutherland, H.J. CD133 (AC133) expression on AML cells and progenitors. Cytotherapy. 3, 449-459 (2001).
11. Uchida, N. et al. Direct isolation of human central nervous system stem cells. Proc. Natl. Acad Sci. USA 97, 14720-14725 (2000).
12. Singh, S. K. et al. Identification of human brain tumour initiating cells. Nature. 432, 396-401 (2004).
13. Bussolati, B. et al. Isolation of renal progenitor cells from adult human kidney. Am. J. Pathol. 166, 545-555 (2005).
14. Florek, M. et al. Prominin-1/CD133, a neural and hematopoietic stem cell marker, is expressed in adult human differentiated cells and certain types of kidney cancer. Cell Tissue Res. 319, 15-26 (2005).
15. Hermann, P. C.et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell. 1, 313-323 (2007).
16. Peled, A.et al. Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. Science. 283, 845-848 (1999).
17. Zou, Y. R., Kottmann, A. H., Kuroda, M., Taniuchi, I. & Littman, D. R. Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature. 393, 595-599 (1998).
18. Hatch, H. M., Zheng, D., Jorgensen, M. L. & Petersen, B. E. SDF-1alpha/CXCR4: A mechanism for hepatic oval cell activation and bone marrow stem cell recruitment to the injured liver of rats. Cloning Stem Cells. 4, 339-351 (2002).
19. Ratajczak, M. Z. et al. Stem cell plasticity revisited: CXCR4-positive cells expressing mRNA for early muscle, liver and neural cells 'hide out' in the bone marrow. Leukemia. 18, 29-40 (2004).
20. Jung, M. J.,et al. Upregulation of CXCR4 is functionally crucial for maintenance of stemness in drug-resistant non-small cell lung cancer cells. Oncogene. 32, 209-221 (2013).
21. Gassenmaier, M.et al. CXC chemokine receptor 4 is essential for maintenance of renal cell carcinoma-initiating cells and predicts metastasis. Stem Cells. 8, 1467-76 (2013).
22. Singh, S., Singh, U. P., Grizzle, W.E. & Lillard, J.W. Jr. CXCL12-CXCR4 interactions modulate prostate cancer cell migration, metalloproteinase expression and invasion. Lab. Invest. 84, 1666-1676 (2004).
23. Broxmeyer, H.E.et al. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J. Exp. Med. 201, 1307-1318 (2005).
24. Tavor, S.et al. CXCR4 regulates migration and development of human acute myelogenous leukemia stem cells in transplanted NOD/SCID mice. Cancer Res. 64, 2817-2824 (2004).
25. Dubrovska, A. et al. CXCR4 expression in prostate cancer progenitor cells. PLoS One. 7, e31226 (2012).
26. Bertolini, G.et al. Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Proc. Natl. Acad Sci. USA. 106, 16281-16286 (2009).
27. Zhang, J. et al. CD133 expression associated with poor prognosis in ovarian cancer. Mod. Pathol. 25, 456-464 (2012).
28. Steg, A.D.et al. Stem cell pathways contribute to clinical chemoresistance in ovarian cancer. Clin. Cancer Res. 18, 869-881 (2012).
29. Curley, M.D.et al. CD133 expression defines a tumor initiating cell population in primary human ovarian cancer. Stem Cells. 27, 2875-2883 (2009).
30. Kang, K.S.et al. CD24(+ ) ovary cancer cells exhibit an invasive mesenchymal phenotype. Biochem Biophys Res. Commun. 432, 333-338 (2012).
31. Ji, Y.I.et al. Expression patterns of Thymosin beta4 and cancer stem cell marker CD133 in ovarian cancers. Pathol. Oncol. Res. 19, 237-245 (2013).
32. Vaughan, S.et al. Rethinking ovarian cancer: Recommendations for improving outcomes. Nat. Rev. Cancer. 11, 719-25 (2011).
33. Rasheed, Z.A., Kowalski, J., Smith, B.D. & Matsui, W. Concise review: Emerging concepts in clinical targeting of cancer stem cells. Stem Cells. 29, 883-7 (2011).
34. Zhou, B.B. et al. Tumour-initiating cells: Challenges and opportunities for anticancer drug discovery. Nat. Rev. Drug Discov. 8, 806-823 (2009).
35. Ricci, F.et al. ALDH enzymatic activity and CD133 positivity and response to chemotherapy in ovarian cancer patients. Am. J. Cancer Res. 3, 221-9 (2013).
36. Flesken-Nikitin, A. et al. Ovarian surface epithelium at the junction area contains a cancer-prone stem cell niche. Nature. 495, 241-5 (2013).
37. Skubitz, A.P.et al. Targeting CD133 in an in vivo ovarian cancer model reduces ovarian cancer progression. Gynecol Oncol. 130, 579-87 (2013).
38. Zhang, J. et al. CD133 expression associated with poor prognosis in ovarian cancer. Mod. Pathol. 25, 456-64 (2012).
39. Barbolina, M.V. et al. Microenvironmental regulation of chemokine (C-X-C-motif) receptor 4 in ovarian carcinoma. Mol. Cancer Res. 8, 653-64 (2010).
40. Jiang, Y.P., Wu, X.H., Shi, B., Wu, W.X. & Yin, G.R. Expression of chemokine CXCL12 and its receptor CXCR4 in human epithelial ovarian cancer: An independent prognostic factor for tumor progression. Gynecol Oncol. 103, 226-233 (2007).
41. Scotton, C.J., Wilson, J.L., Milliken, D., Stamp, G. & Balkwill, F.R. Epithelial cancer cell migration: A role for chemokine receptors? Cancer Res. 61, 4961-5 (2001
42. Scotton, C.J. et al. Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer. Cancer Res. 62, 5930-8 (2002).
43. Popple, A.et al. The chemokine, CXCL12, is an independent predictor of poorsurvival in ovarian cancer. British Journal of Cancer. 106, 1306-1313 (2012).
44. Broxmeyer, H.E. et al. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J. Exp. Med. 201, 1307-18 (2005).
45. Debnath, B.et al. Small molecule inhibitors of CXCR4. Theranostics. 3, 47-75 (2013).
46. Portella, L.et al. Preclinical development of a novel class of CXCR4antagonist impairing solid tumors growth and metastases. PLoS One; 8, e74548 (2013).
47. Moghaddas Gholami, A. et al. Global proteome analysis of the NCI-60 cell line panel. Cell Rep. 4, 609-20 (2013).